ANTIPLATELET DRUGS MARKET ANALYSIS

Antiplatelet Drugs Market, by Drug Class (Irreversible Cyclooxygenase (COX) Inhibitors, Adenosine Diphosphate (ADP) Receptor Inhibitors, Glycoprotein IIB/IIIA Inhibitors, Adenosine Reuptake Inhibitors, and Thromboxane Inhibitors and Phosphodiesterase Inhibitors), by Mode of Administration (Oral and Intravenous), by Application (Angioplasty, Arterial Thrombosis, Myocardial Infarction, Percutaneous Coronary Interventions, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

Published In : Jul 2022
Code : CMI2190
Pages :185
Formats :
Excel and PDF
Industry : Pharmaceutical

Market Challenges And Opportunities

Restraints & Challenges:

Limitations in efficacy, safety, and tolerability of some antiplatelet drugs

Global Antiplatelet Drugs Market: Restraint

The major factors that hinder growth of the global antiplatelet drugs market include limitations in efficacy, safety, and tolerability of some antiplatelet drugs. For instance, in July 2018, according to National Center for Biotechnology Information, antiplatelet drugs can irritate lining of the stomach that leads to gastrointestinal side effects such as indigestion and stomach aches. Moreover, patients using these drugs can be more prone to nosebleeds, bruising or bleeding for longer than usual since they reduce the ability of the blood to clot. According to the Journal of Clinical Gastroenterology 2018 report, most spontaneous bleeding in patients treated with antiplatelet drugs occurs in the gastrointestinal tract, with an incidence of 2-3% with dual antiplatelet therapy.